Ceftaroline Restores Daptomycin Activity against Daptomycin-Nonsusceptible Vancomycin-Resistant Enterococcus faecium
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium (VRE) strains are a formidable emerging threat to patients with comorbidities, leaving few therapeutic options in cases of severe invasive infections. Using a previously characterized isogenic pair of VRE strains from the same patient differing in their daptomycin susceptibilities (Etest MICs of 0.38 mg/liter and 10 mg/liter), we examined the effect of ceftaroline, ceftriaxone, and ampicillin on membrane fluidity and susceptibility of VRE to surface binding and killing by daptomycin and human cathelicidin antimicrobial peptide LL37. Synergy was noted in vitro between daptomycin, ampicillin, and ceftaroline for the daptomycin-susceptible VRE strain, but only ceftaroline showed synergy against the daptomycin-nonsusceptible VRE strain (∼2 log 10 CFU reduction at 24 h). Ceftaroline cotreatment increased daptomycin surface binding with an associated increase in membrane fluidity and an increase in the net negative surface charge of the bacteria as evidenced by increased poly- l -lysine binding. Consistent with the observed biophysical changes, ceftaroline resulted in increased binding and killing of daptomycin-nonsusceptible VRE by human cathelicidin LL37. Using a pair of daptomycin-susceptible/nonsusceptible VRE strains, we noted that VRE is ceftaroline resistant, yet ceftaroline confers significant effects on growth rate as well as biophysical changes on the cell surface of VRE that can potentiate the activity of daptomycin and innate cationic host defense peptides, such as cathelicidin. Although limited to just 2 strains, these finding suggest that additional in vivo and in vitro studies need to be done to explore the possibility of using ceftaroline as adjunctive anti-VRE therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of in vitro evaluations [214][215][216] suggested that ampicillin and ceftaroline in combination with daptomycin demonstrate the greatest synergistic activity compared with other β-lactam-daptomycin combinations.”
From Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association (2015) · cites this paper as [215]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of multidrug-resistant enterococcal infections
Arias, C. A., Contreras, G. A., & Murray, B. E. (2010) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03214.x · Cited by 388
Genetic Basis for In Vivo Daptomycin Resistance in Enterococci
Arias, C. A., Panesso, D., McGrath, D. M., Qin, X., Mojica, M. F., Miller, C., Diaz, L., Tran, T. T., Rincon, S., Barbu, E. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011138 · Cited by 377
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Dhand, A., Bayer, A. S., Pogliano, J., Yang, S.-J., Bolaris, M., Nizet, V., Wang, G., & Sakoulas, G. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir340 · Cited by 252 · cited 2×
“MICs to cathelicidin LL37 in RPMI-5% LB for strains 8019 and 5938 were 2 M and 4 M, respectively, consistent with tracking of the susceptibility of daptomycin to cationic antimicrobial peptides (14).”
Self-citationPharmacokinetics of ceftriaxone in humans
Patel, I. H., Chen, S., Parsonnet, M., Hackman, M. R., Brooks, M. A., Konikoff, J., & Kaplan, S. A. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.20.5.634 · Cited by 244
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment
Dryden, M. S. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr072 · Cited by 198
Sakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176 · cited 6×
“assays were performed using flow cytometry methods previously described (5).”
BackgroundMethodResultInfluentialSelf-citationMishra, N. N., Bayer, A. S., Tran, T. T., Shamoo, Y., Mileykovskaya, E., Dowhan, W., Guan, Z., & Arias, C. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043958 · Cited by 168
Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus
Sakoulas, G., Okumura, C. Y. M., Thienphrapa, W., Olson, J., Nonejuie, P., Dam, Q., Dhand, A., Pogliano, J., Yeaman, M. R., Hensler, M. E., et al. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1100-7 · Cited by 153
Self-citationDaptomycin Nonsusceptible Enterococci: An Emerging Challenge for Clinicians
Kelesidis, T., Humphries, R., Uslan, D. Z., & Pegues, D. A. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq113 · Cited by 146
Self-citation
Research works printed but not linked: 1
- CLSI. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Mechanisms of antibiotic resistance in enterococci
Miller, W. R., Munita, J. M., & Arias, C. A. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956092 · Cited by 772
“Indeed, combinations of DAP with ampicillin, ceftriaxone and ceftaroline have been noted to be synergistic in vitro and to improve clinical outcomes of patients failing DAP therapy [71–73].”
BackgroundCrank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard, K. E., & Overhage, J. (2021) · Antibiotics · doi:10.3390/antibiotics10060650 · Cited by 270
“One study found that the combination of DAP and CPT increased the amount of LL-37 binding to the surface of VRE, and therefore sensitizes the bacteria to LL-37 [209].”
BackgroundMechanisms of drug resistance: daptomycin resistance
Tran, T. T., Munita, J. M., & Arias, C. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12948 · Cited by 234
Whole-Genome Analyses of Enterococcus faecium Isolates with Diverse Daptomycin MICs
Diaz, L., Tran, T. T., Munita, J. M., Miller, W. R., Rincon, S., Carvajal, L. P., Wollam, A., Reyes, J., Panesso, D., Rojas, N. L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02686-14 · Cited by 139
Smith, J. R., Barber, K. E., Raut, A., Aboutaleb, M., Sakoulas, G., & Rybak, M. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv007 · Cited by 148
Self-citationEvolving Resistance Among Gram-positive Pathogens
Munita, J. M., Bayer, A. S., & Arias, C. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ523 · Cited by 153
Vancomycin-Resistant Enterococci
Miller, W. R., Murray, B. E., Rice, L. B., & Arias, C. A. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.006 · Cited by 153
Britt, N. S., Potter, E. M., Patel, N., & Steed, M. E. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw815 · Cited by 120
“Unfortunately, some other potentially synergistic agents, such as ceftaroline, were not utilized enough to adequately power a stratified analysis [37].”
BackgroundShukla, B. S., Shelburne, S. A., Reyes, K., Kamboj, M., Lewis, J. D., Rincón, S., Reyes, J., Carvajal, L. P., Panesso, D., Sifri, C. D., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw173 · Cited by 109
Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms
Sy, C.-L., Chen, P., Cheng, C.-W., Huang, L.-J., Wang, C.-H., Chang, T., Chang, Y., Chang, C.-J., Hii, I.-M., Hsu, Y., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.02.001 · Cited by 123
Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections
Cairns, K. A., Udy, A. A., Peel, T. N., Abbott, I. J., Dooley, M. J., & Peleg, A. Y. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-22 · Cited by 119
Combatting resistant enterococcal infections: a pharmacotherapy review
Mercuro, N. J., Davis, S. L., Zervos, M., & Herc, E. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1479397 · Cited by 98
Yim, J., Smith, J. R., & Rybak, M. J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1922 · Cited by 100
“work.(46) Against the daptomycin-susceptible parent E.”
BackgroundInfluentialDhand, A., & Sakoulas, G. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.005 · Cited by 80
Self-citationMunita, J. M., Mishra, N. N., Alvarez, D., Tran, T. T., Diaz, L., Panesso, D., Reyes, J., Murray, B. E., Adachi, J. A., Bayer, A. S., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu642 · Cited by 70
“Data in staphylococci and enterococci suggest that the combination of DAP and β-lactams can yield in vitro synergism and therapeutic success against DAP-R isolates [10].”
Sparo, M. D., Delpech, G., & Allende, N. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.03073 · Cited by 78
Fiore, M., Maraolo, A. E., Gentile, I., Borgia, G., Leone, S., Sansone, P., Passavanti, M. B., Aurilio, C., & Pace, M. C. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i30.1166 · Cited by 68
Avery, L. M., Kuti, J. L., Weisser, M., Egli, A., Rybak, M. J., Zasowski, E. J., Arias, C. A., Contreras, G., Chong, P. P., Aitken, S. L., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy749 · Cited by 58
Bacterial cell membranes and their role in daptomycin resistance: A review
Nguyen, A. H., Hood, K. S., Mileykovskaya, E., Miller, W. R., & Tran, T. T. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1035574 · Cited by 66
“disrupt cell wall biosynthesis is also supported by multiple in vitro and ex vivo studies where synergy or re-sensitization of DAP was observed upon combination with cell-wall acting antibiotics such as β-lactams (Dhand et al., 2011; Sakoulas et al., 2013; Sakoulas et al., 2014; Smith et al., 2015a; Smith et al., 2015…”
BackgroundSmith, J. R., Barber, K. E., Raut, A., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-15 · Cited by 62
“be imperative for the synergistic effect (24, 25).”
BackgroundSakoulas, G., Olson, J., Yim, J., Singh, N. B., Kumaraswamy, M., Quach, D., Rybak, M. J., Pogliano, J., & Nizet, V. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01192-16 · Cited by 60
Self-citationWhat’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Advances in the therapy of bacterial bloodstream infections
Giannella, M., Bartoletti, M., Gatti, M., & Viale, P. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.11.001 · Cited by 52
Enterococcal Endocarditis Revisited
Pericàs, J. M., Zboromyrska, Y., Cervera, C., Castañeda, X., Almela, M., García-de-la-Mària, C., Mestres, C. A., Falces, C., Quintana, E., Ninot, S. P. I., et al. (2015) · Future Microbiology · doi:10.2217/fmb.15.46 · Cited by 60
Kebriaei, R., Rice, S., Singh, K. V., Stamper, K. C., Dinh, A. Q., Ríos, R., Díaz, L., Murray, B. E., Munita, J. M., Tran, T. T., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00315-18 · Cited by 45
Werth, B. J., Barber, K. E., Tran, N. N., Nonejuie, P., Sakoulas, G., Pogliano, J., & Rybak, M. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku386 · Cited by 45
Self-citationDaptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci
Munita, J. M., Murray, B. E., & Arias, C. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.08.002 · Cited by 45
Hindler, J. A., Wong‐Beringer, A., Charlton, C. L., Miller, S. A., Kelesidis, T., Carvalho, M., Sakoulas, G., Nonejuie, P., Pogliano, J., Nizet, V., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05077-14 · Cited by 44
“In addition, we previously demonstrated for isolate 5938 (which is the same strain as Efm16) that treatment with 50 g/ml ampicillin caused an increase in cell wall thickness and increased LL-37 binding and activity (18).”
BackgroundMethodInfluentialSelf-citationBartash, R. M., & Nori, P. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.07.019 · Cited by 49
Novel Strategies for the Management of Vancomycin-Resistant Enterococcal Infections
Contreras, G., Munita, J. M., & Arias, C. A. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0680-y · Cited by 50
Snyder, A. D. H., Werth, B. J., Nonejuie, P., McRoberts, J. P., Pogliano, J., Sakoulas, G., Yim, J., Singh, N. B., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00687-16 · Cited by 41
Self-citationClinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia
Moise, P. A., Sakoulas, G., McKinnell, J. A., Lamp, K. C., DePestel, D. D., Yoon, M., Reyes, K., & Zervos, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.008 · Cited by 41
Self-citationUppu, D. S. S. M., Manjunath, G. B., Yarlagadda, V., Kaviyil, J. E., Ravikumar, R., Krishnamoorthy, P., Shome, B. R., & Haldar, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119422 · Cited by 40
“One of the promising strategies to target multi-drug resistant (MDR) bacteria is by using either combination of two antibiotics or combination of antibiotics and non-antibiotics/adjuvants [5–16].”
BackgroundBenamu, E., & Deresinski, S. C. (2018) · F1000Research · doi:10.12688/f1000research.11831.1 · Cited by 44
“This leads to enhanced membrane depolarization, increased fluidity, and susceptibility to killing by cationic calcium-daptomycin and a diverse range of human cationic antimicrobial peptides, notably cathelicidin LL-37 164,165 .”
BackgroundSakoulas, G., Geriak, M., & Nizet, V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy557 · Cited by 46
Self-citationMultidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?
Brunel, A.-S., & Guery, B. P. (2017) · Swiss Medical Weekly · doi:10.4414/smw.2017.14553 · Cited by 47
Therapeutic options for vancomycin-resistant enterococcal bacteremia
Barber, K. E., King, S. T., Stover, K. R., & Pogue, J. M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1001839 · Cited by 39
Enterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species
Arias, C. A., & Murray, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00202-2 · Cited by 40
Britt, N. S., Potter, E. M., Patel, N., & Steed, M. E. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02216-16 · Cited by 38
Dalbavancin is active in vitro against biofilms formed by dalbavancin-susceptible enterococci
Neudorfer, K., Schmidt-Malan, S. M., & Patel, R. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.09.015 · Cited by 36
Abbo, L. M., Shukla, B. S., Giles, A. B., Aragon, L., Jiménez, A., Camargo, J. F., Simkins, J., Sposato, K. A., Tran, T. T., Díaz, L., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy903 · Cited by 36
Morrisette, T., Lev, K. L., Kebriaei, R., Abdul‐Mutakabbir, J. C., Stamper, K. C., Morales, S., Lehman, S. M., Canfield, G. S., Duerkop, B. A., Arias, C. A., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00993-20 · Cited by 35
Pereira, M. R., Rana, M. M., & Practice, T. A. I. C. O. (2019) · Clinical Transplantation · doi:10.1111/ctr.13611 · Cited by 35
Lee, B. J., Vu, B. N., Seddon, A. N., Hodgson, H. A., & Wang, S. K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020932513 · Cited by 34
Jean, S., Liu, I.-M., Hsieh, P.-C., Kuo, D.-H., Liu, Y.-L., & Hsueh, P. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106763 · Cited by 34
Jahanbakhsh, S., Singh, N. B., Yim, J., Kebriaei, R., Smith, J. R., Lev, K. L., Tran, T. T., Rose, W. E., Arias, C. A., & Rybak, M. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02074-19 · Cited by 35
“Our present study also showed DAP MIC reductions in combinations with -lactams against enterococci (32, 41).”
ResultSelf-citationSmith, J. R., Yim, J., Raut, A., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03006-15 · Cited by 35
Sakoulas, G., Nonejuie, P., Kullar, R., Pogliano, J., Rybak, M. J., & Nizet, V. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04965-14 · Cited by 32
Self-citationChuang, Y., Chen, P., Lin, C., Chen, Y., Wang, J., & Chang, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19986-8 · Cited by 31
Chuang, Y., Lin, H., Yang, J. L., Lin, C. Y., Huang, S. H., Wang, J. T., Chen, Y., & Chang, S. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac164 · Cited by 28
Sharma, P., Sharma, N., Mishra, P., Joseph, J., Mishra, D. K., Garg, P., & Roy, S. (2019) · Pathogens · doi:10.3390/pathogens8010031 · Cited by 25
“pneumoniae meningitis in the presence of ceftaroline [59].”
BackgroundShafiq, I., Bulman, Z. P., Spitznogle, S. L., Osorio, J., Reilly, I. S., Lesse, A. J., Parameswaran, G. I., Mergenhagen, K. A., & Tsuji, B. T. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2016.1277587 · Cited by 34
“Particularly, ceftaroline is thought to overcome MRSA resistance to daptomycin by enhancing daptomycin binding to the cell membrane through changes in membrane fluidity and charge [22,23,25].”
BackgroundEcheverría-Esnal, D., Sorlí, L., Navarrete-Rouco, M. E., Prim, N., Barceló‐Vidal, J., Conde‐Estévez, D., Montero, M., Martín‐Ontiyuelo, C., Horcajada, J. P., & Grau, S. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2223977 · Cited by 24
“Other models showed that ceftaroline could also be used in combination with daptomycin [128].”
BackgroundCombination antibiotic therapy for the treatment of infective endocarditis due to enterococci
Leone, S., Noviello, S., & Esposito, S. (2015) · Infection · doi:10.1007/s15010-015-0836-0 · Cited by 22
“faecium because a reversion to daptomycin susceptibility [47].”
BackgroundChuang, Y., Wang, J., Yang, J.-L., Lin, C., Huang, S., Chen, Y., & Chang, S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.017 · Cited by 22
Moing, V. L., Bonnet, É., Cattoir, V., Chirouze, C., Deconinck, L., Duval, X., Hoen, B., Issa, N., Lecomte, R., Tattevin, P., et al. (2024) · Infectious Diseases Now · doi:10.1016/j.idnow.2024.105011 · Cited by 19
Growth Arrest of Staphylococcus aureus Induces Daptomycin Tolerance via Cell Wall Remodelling
Ledger, E. V. K., & Edwards, A. M. (2023) · mBio · doi:10.1128/mbio.03558-22 · Cited by 21
Pericàs, J. M., García-de-la-Mària, C., Brunet, M., Armero, Y., García-González, J. A., Casals, G., Almela, M., Quintana, E., Falces, C., Ninot, S. P. I., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx016 · Cited by 21
Rolston, K. V. I., Jamal, M. A., Nesher, L., Shelburne, S. A., RAAD, I. I., & Prince, R. A. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.016 · Cited by 14
“and is not recommended as monotherapy for these organisms, it may potentiate the activity of agents such as DAP against non-susceptible strains [35].”
BackgroundWerth, B. J., & Shireman, L. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02235-16 · Cited by 16
Carter, G. P., Harjani, J. R., Li, L. Z., Pitcher, N. P., Nong, Y., Riley, T. V., Williamson, D. A., Stinear, T. P., Baell, J. B., & Howden, B. P. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky064 · Cited by 13
Lewis, J. D., Barros, A. J., & Sifri, C. D. (2018) · Transplant Infectious Disease · doi:10.1111/tid.12856 · Cited by 13
Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections
Turner, A. M., Kinsella, P. M., Miller, W. R., Carter, G. P., Tran, T. T., Howden, B. P., & Arias, C. A. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01060-24 · Cited by 17
“On the other hand, some studies have shown that exposure to β-lactams reduces the net positive bacterial surface charge and leads to an increase in DAP binding (43).”
Chuang, Y., Lin, H., Wang, J., Yang, J., Lin, C., Huang, S., Chen, Y., & Chang, S. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113710 · Cited by 12
Lê, J., Dam, Q., Schweizer, M. L., Thienphrapa, W., Nizet, V., & Sakoulas, G. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2682-0 · Cited by 10
“Ampicillin and ceftaroline provide similar immunity-boosting activity against ampicillin- and vancomycin-resistant Enterococcus faecium [15, 16].”
BackgroundSelf-citationCheng, M. P., Lawandi, A., Butler‐Laporte, G., Paquette, K., & Lee, T. C. (2018) · Trials · doi:10.1186/s13063-018-2668-6 · Cited by 9
“These interactions have even demonstrated restoration of daptomycin susceptibility to previously non-susceptible Enterococci [25].”
BackgroundMeurer, M., de Buhr, N., Unger, L. M., Bonilla, M. C., Seele, J., Nau, R., Baums, C. G., Gutsmann, T., Schwarz, Š., & von Köckritz‐Blickwede, M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02911 · Cited by 8
“Interestingly, some antibiotics can increase the efficacy and binding capacity of AMPs to bacteria (Sakoulas et al., 2014).”
BackgroundSakoulas, G., Kumaraswamy, M., Nonejuie, P., Werth, B. J., Rybak, M. J., Pogliano, J., Rice, L. B., & Nizet, V. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00486-15 · Cited by 6
Self-citationMcCarthy, M. W., Baker, T., Satlin, M. J., & Walsh, T. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-77674-3_15 · Cited by 7
Pharmacotherapies for multidrug-resistant gram-positive infections: current options and beyond
Leone, S., Pezone, I., Pisaturo, M., McCaffery, E., Alfieri, A., & Fiore, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2367003 · Cited by 4
Combination Antibiotic Therapy for Orthopedic Infections
Bonnet, É., & Lourtet-Hascoët, J. (2025) · Antibiotics · doi:10.3390/antibiotics14080761 · Cited by 4
“In cases of BJI caused by MRSA and enterococci, the combination of daptomycin and ceftobiprole may help reduce the likelihood of developing resistance and infection relapse [86,87].”
Beindorf, P., Kovalenko, O., Ulrich, S., Geißler, H., Korbel, R., Schwaiger, K., Dorn‐In, S., & Cuesta, I. E. (2022) · Biology · doi:10.3390/biology11070985 · Cited by 4
“We also tested resistance against the only existing 5GC, ceftaroline, which can be used in combination with daptomycin for the treatment of nondaptomycin-susceptible vancomycin-resistant Enterococci [43].”
BackgroundAdema, J. L., Ahiskali, A., Fida, M., Hornback, K. M., Stevens, R. W., & Rivera, C. G. (2023) · Pathogens · doi:10.3390/pathogens12050703 · Cited by 6
“There are multiple proposed theories for why these agents work synergistically together, including that CPT decreases cell wall thickness, increases cell wall fluidity, and decreases net surface charge, thus increasing DAP susceptibility [78].”
BackgroundNew advances in management and treatment of cardiac implantable electronic devices infections
Russo, A., Serraino, R., Serapide, F., Trecarichi, E. M., & Torti, C. (2023) · Infection · doi:10.1007/s15010-023-02130-8 · Cited by 9
Enterococcal Infections in Adults
Reyes, K., Zervos, M., & John, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_3 · Cited by 5
Prevalence of High Level Gentamicin Resistance among the Clinical Isolates of Enterococci Species
Arundathi, H. A., Prakash, N., Halesh, H. L., & Siddesh, K. (2022) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.16.2.23 · Cited by 3
Pincus, N. B., Joshi, T., Gatesy, S. W. M., Al-Heeti, O., Moore, W. J., & Bachta, K. E. R. (2022) · IDCases · doi:10.1016/j.idcr.2022.e01593 · Cited by 4
Paz, D. L., & Tattevin, P. (2026) · Critical Care · doi:10.1186/s13054-026-06011-y · Cited by 3
A Clinician’s Guide to the Treatment of Vancomycin Resistant Enterococci Bacteremia and Endocarditis
Soule, D., & Climo, M. W. (2016) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-016-0082-8 · Cited by 2
Kang, J. E., Byun, J., Kim, Y., & Park, S. E. (2022) · Pediatric Infection & Vaccine · doi:10.14776/piv.2022.29.e11 · Cited by 2
Moing, V. L., Bonnet, É., Cattoir, V., Chirouze, C., Deconinck, L., Duval, X., Hoen, B., Issa, N., Lecomte, R., Tattevin, P., et al. (2024) · Médecine et Maladies Infectieuses Formation · doi:10.1016/j.mmifmc.2024.11.071 · Cited by 1
Krishnan, A., Rajakumar, I., & Salmon, J. (2025) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2023-0038 · Cited by 1
Yang, C., Jann-Tay, W., Yang, J.-L., & Chuang, Y. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s570238 · Cited by 2
Cañas, M.-A., García‐González, J., Luque-Paz, D., Cuervo, G., Krivak, F., Nin-Blanch, J., Meneses, M. H., Falces, C., Maristany, M., Perissinotti, A., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag136 · Cited by 2
Multidrug-Resistant Organisms: Considerations in Antibiotic Selection and Administration
Arora, H. S., Gupta, S., Sutton, J. D., Abdel‐Haq, N., & Molloy, L. M. (2015) · Journal of Pediatric Intensive Care · doi:10.1055/s-0035-1556751 · Cited by 2
Cave, K., & Gould, I. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00138-9 · Cited by 2
Advances in the Diagnosis and Treatment of Infective Endocarditis
Turner, R. B., & Schwartz, J. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch010
Crum‐Cianflone, N. F. (2017) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000504
Smith, J. R., Claeys, K. C., Zasowski, E. J., Yim, J., & Rybak, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_21
Combined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Enterococcal and Viridans Streptococcal Infections
McNeil, J. C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-82763-8.00084-4
Foster, R. A., Cluck, D. B., Rogers, D. J., White, B. P., Daut, L., Bland, C. M., Webb, B. J., Henao‐Martínez, A. F., & Chastain, D. B. (2026) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361261499816
Metadata
- Authors
- Sakoulas, G., Rose, W., Nonejuie, P., Olson, J., Pogliano, J., Humphries, R., & Nizet, V.
- Affiliations
- University of California San Diego (US)
- University of Wisconsin–Madison (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-03
- Volume
- 58
- Issue
- 3
- Pages
- 1494-1500
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3957885
- OpenAlex
- W2140427502
- Semantic Scholar
- 7cd7eeff4f3f8161c4beafcf1621194b9b5cae51
- Cited by
- 94
- References
- 23
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 9 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 12 · 2017: 14 · 2016: 8 · 2015: 16 · 2014: 7
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Great Lakes Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research
- Medicines Company
- Forest Laboratories
- National Institute of General Medical Sciences (R01GM073898)
- National Institute of Allergy and Infectious Diseases (U54AI057153, R01AI052453, AI057153, R37AI052453)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54 HD071600-01 09/26/2011-06/30/2016, U54HD071600)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Immunology and Microbiology › Microbiology › Antimicrobial Peptides and Activities
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- ceftaroline, daptomycin, vancomycin-resistant Enterococcus faecium, daptomycin resistance, antibiotic synergy, membrane fluidity, cell surface charge, antimicrobial peptides, adjunctive therapy, ceftriaxone, ampicillin, isogenic strains
- MeSH terms
- Ceftaroline, Anti-Bacterial Agents, Cell Wall, Cephalosporins, Drug Synergism, Membrane Fluidity, Microbial Sensitivity Tests, Enterococcus faecium, Daptomycin, Vancomycin Resistance, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.